Multicriteria decision analysis in health care decision in oncology: a systematic review

被引:5
作者
Campolina, Alessandro Goncalves [1 ,2 ]
Suzumura, Erica Aranha [1 ]
Quan Nha Hong [3 ]
de Soarez, Patricia Coelho [1 ]
机构
[1] Univ Sao Paulo, Fac Med Fmusp, Dept Med Prevent, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil
[2] Univ Sao Paulo, Fac Med Fmusp, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil
[3] UCL, EPPI Ctr, UCL Social Res Inst, London, England
关键词
Cancer; health technology assessment; MCDA; multicriteria decision analysis; Technology Assessment; biomedical; MULTIPLE CRITERIA; TECHNOLOGY-ASSESSMENT; CANCER CARE; AMERICAN SOCIETY; VALUE FRAMEWORKS; MCDA; MEDICINES; BENEFIT; COST; HTA;
D O I
10.1080/14737167.2022.2019580
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction Multicriteria decision analysis (MCDA) has been used to inform health decisions in health technology assessments (HTA) processes. This is particularly important to complex treatment decisions in oncology. Areas covered Five databases (PubMed, EMBASE, LILACS, Web of Science and CRD's NHS Economic Evaluation Database) were searched for studies comparing health technologies in oncology, involving the concept MCDA. The ISPOR MCDA Good Practices Guidelines were used to assess the reporting quality. Study selection, appraisal, and data extraction were performed by two reviewers. Fifteen studies were included. The main decision problem was related to health technology assessment of cancer treatments. Clinicians and public health experts were the most frequent stakeholders. The most frequently included criteria comprised therapeutic benefit, and socio-economic impact. Value measurement approach, direct rating techniques, and additive model for aggregation were used in most studies. Uncertainty analysis revealed the impact of posology and costs on the studies' results. All studies showed some level of overlapping decision criteria. Expert opinion There is considerable diversity of methods in MCDA for healthcare decision-making in oncology. The evidence presented can serve as a resource when considering which stakeholders, criteria, and techniques to include in future MCDA studies in oncology.
引用
收藏
页码:365 / 380
页数:16
相关论文
共 78 条
  • [1] Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis
    Adunlin, Georges
    Diaby, Vakaramoko
    Xiao, Hong
    [J]. HEALTH EXPECTATIONS, 2015, 18 (06) : 1894 - 1905
  • [2] Multicriteria decision analysis in oncology
    Adunlin, Georges
    Diaby, Vakaramoko
    Montero, Alberto J.
    Xiao, Hong
    [J]. HEALTH EXPECTATIONS, 2015, 18 (06) : 1812 - 1826
  • [3] Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework
    Angelis, A.
    Linch, M.
    Montibeller, G.
    Molina-Lopez, T.
    Zawada, A.
    Orzel, K.
    Arickx, F.
    Espin, J.
    Kanavos, P.
    [J]. SOCIAL SCIENCE & MEDICINE, 2020, 246
  • [4] Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
    Angelis, Aris
    Lange, Ansgar
    Kanavos, Panos
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (01) : 123 - 152
  • [5] Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting
    Angelis, Aris
    Montibeller, Gilberto
    Hochhauser, Daniel
    Kanavos, Panos
    [J]. BMC MEDICAL INFORMATICS AND DECISION MAKING, 2017, 17
  • [6] Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework
    Angelis, Aris
    Kanavos, Panos
    [J]. SOCIAL SCIENCE & MEDICINE, 2017, 188 : 137 - 156
  • [7] [Anonymous], 2020, DRUG AB
  • [8] Framework for Drug Formulary Decision Using Multiple-Criteria Decision Analysis
    Babashov, Vusal
    Ben Amor, Sarah
    Reinhardt, Gilles
    [J]. MEDICAL DECISION MAKING, 2020, 40 (04) : 438 - 447
  • [9] Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
    Bach, Peter B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (06) : 626 - 633
  • [10] Incorporating Equity-Efficiency Interactions in Cost-Effectiveness Analysis-Three Approaches Applied to Breast Cancer Control
    Baeten, Stefan A.
    Baltussen, Rob M. P. M.
    Uyl-de Groot, Carin A.
    Bridges, John
    Niessen, Louis W.
    [J]. VALUE IN HEALTH, 2010, 13 (05) : 573 - 579